Elsa Daniela Ibañez-Prada

Elsa Daniela Ibañez-Prada

Auto-generated profile, based on publicly available information

Elsa Daniela Ibañez-Prada

Affiliations Unisabana Center for Translational Science, Universidad de La Sabana, Chía, Colombia, Clínica Universidad de La Sabana, Chía, Colombia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Critical Care
Verified
Journal Article
Open access
PDF file
LRLuis F Reyes
Luis F Reyes
EGEsteban Garcia
Esteban Garcia
EIElsa D. Ibáñez-Prada
Elsa D. Ibáñez-Prada
CSCristian Camilo Serrano-Mayorga
Cristian Camilo Serrano-Mayorga
Yuli Viviana Fuentes-BarreiroYuli Viviana Fuentes-Barreiro
Yuli Viviana Fuentes-Barreiro
GWGrant Waterer
Grant Waterer
Introduction: Patients with community-acquired pneumonia (CAP) admitted to the intensive care unit (ICU) have high mortality rates during the acute infection and up to ten years thereafter. Recommendations from international CAP guidelines include macrolide-based treatment. However, there is no data on the long-term outcomes of this recommendation. Therefore, we aimed to determine the impact of macrolide-based therapy on long-term mortality in this population. Methods: Registered patients in the MIMIC-IV database 16 years or older and admitted to the ICU due to CAP were included. Multivariate analysis, targeted maximum likelihood estimation (TMLE) to simulate a randomised controlled trial, and survival analyses were conducted to test the effect of macrolide-based treatment on mortality six-month (6 m) and twelve-month (12 m) after hospital admission. A sensitivity analysis was performed excluding patients with Pseudomonas aeruginosa or MRSA pneumonia to control for Healthcare-Associated Pneumonia (HCAP). Results: 3775 patients were included, and 1154 were treated with a macrolide-based treatment. The non-macrolide-based group had worse long-term clinical outcomes, represented by 6 m [31.5 (363/1154) vs 39.5 (1035/2621), p < 0.001] and 12 m mortality [39.0 (450/1154) vs 45.7 (1198/2621), p < 0.001]. The main risk factors associated with long-term mortality were Charlson comorbidity index, SAPS II, septic shock, and respiratory failure. Macrolide-based treatment reduced the risk of dying at 6 m [HR (95% CI) 0.69 (0.60, 0.78), p < 0.001] and 12 m [0.72 (0.64, 0.81), p < 0.001]. After TMLE, the protective effect continued with an additive effect estimate of − 0.069. Conclusion: Macrolide-based treatment reduced the hazard risk of long-term mortality by almost one-third. This effect remains after simulating an RCT with TMLE and the sensitivity analysis for the HCAP classification.

21 October 2024 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
EPEkaterina Pazukhina
Ekaterina Pazukhina
EGEsteban Garcia-Gallo
Esteban Garcia-Gallo
LRLuis F Reyes
Luis F Reyes
AKAnders Benjamin Kildal
Anders Benjamin Kildal
WJWaasila Jassat
Waasila Jassat
LSLouise Sigfrid
Louise Sigfrid
Introduction A proportion of people develop Long Covid after acute COVID-19, but with most studies concentrated in high-income countries (HICs), the global burden is largely unknown. Our study aims to characterise long-term COVID-19 sequelae in populations globally and compare the prevalence of reported symptoms in HICs and low-income and middle-income countries (LMICs). Methods A prospective, observational study in 17 countries in Africa, Asia, Europe and South America, including adults with confirmed COVID-19 assessed at 2 to <6 and 6 to <12 months post-hospital discharge. A standardised case report form developed by International Severe Acute Respiratory and emerging Infection Consortium’s Global COVID-19 Follow-up working group evaluated the frequency of fever, persistent symptoms, breathlessness (MRC dyspnoea scale), fatigue and impact on daily activities. Results Of 11 860 participants (median age: 52 (IQR: 41–62) years; 52.1% females), 56.5% were from HICs and 43.5% were from LMICs. The proportion identified with Long Covid was significantly higher in HICs vs LMICs at both assessment time points (69.0% vs 45.3%, p<0.001; 69.7% vs 42.4%, p<0.001). Participants in HICs were more likely to report not feeling fully recovered (54.3% vs 18.0%, p<0.001; 56.8% vs 40.1%, p<0.001), fatigue (42.9% vs 27.9%, p<0.001; 41.6% vs 27.9%, p<0.001), new/persistent fever (19.6% vs 2.1%, p<0.001; 20.3% vs 2.0%, p<0.001) and have a higher prevalence of anxiety/depression and impact on usual activities compared with participants in LMICs at 2 to <6 and 6 to <12 months post-COVID-19 hospital discharge, respectively. Conclusion Our data show that Long Covid affects populations globally, manifesting similar symptomatology and impact on functioning in both HIC and LMICs. The prevalence was higher in HICs versus LMICs. Although we identified a lower prevalence, the impact of Long Covid may be greater in LMICs if there is a lack of support systems available in HICs. Further research into the aetiology of Long Covid and the burden in LMICs is critical to implement effective, accessible treatment and support strategies to improve COVID-19 outcomes for all.

26 January 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
LRLuis F Reyes
Luis F Reyes
Antoni TorresAntoni Torres
Antoni Torres
JOJuan Olivella-Gomez
Juan Olivella-Gomez
EIElsa D. Ibáñez-Prada
Elsa D. Ibáñez-Prada
SNSaad Nseir
Saad Nseir
Ignacio Martin-LoechesIgnacio Martin-Loeches
Ignacio Martin-Loeches
Background: Nosocomial lower respiratory tract infections (nLRTIs) are associated with unfavorable clinical outcomes and significant healthcare costs. nLRTIs include hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and other ICU-acquired pneumonia phenotypes. While risk factors for mortality in these infections are critical to guide preventive strategies, it remains unclear whether they vary based on their requirement of invasive mechanical ventilation (IMV) at any point during the hospitalization. Objectives: This study aims to identify risk factors associated with short- and long-term mortality in patients with nLRTIs, considering differences between those requiring IMV and those who do not. Methods: This multinational prospective cohort study included ICU-admitted patients diagnosed with nLRTI from 28 hospitals across 13 countries in Europe and South America between May 2016 and August 2019. Patients were selected based on predefined inclusion and exclusion criteria, and clinical data were collected from medical records. A random forest classifier determined the most optimal clustering strategy when comparing pneumonia site acquisition [ward or intensive care unit (ICU)] versus intensive mechanical ventilation (IMV) necessity at any point during hospitalization to enhance the accuracy and generalizability of the regression models. Results: A total of 1060 patients were included. The random forest classifier identified that the most efficient clustering strategy was based on ventilation necessity. In total, 76.4% of patients [810/1060] received IMV at some point during the hospitalization. Diabetes mellitus was identified to be associated with 28-day mortality in the non-IMV group (OR [IQR]: 2.96 [1.28–6.80], p = 0.01). The 90-day mortality-associated factor was MDRP infection (1.98 [1.13–3.44], p = 0.01). For ventilated patients, chronic liver disease was associated with 28-day mortality (2.38 [1.06–5.31] p = 0.03), with no variable showing statistical and clinical significance at 90 days. Conclusions: The risk factors associated with 28-day mortality differ from those linked to 90-day mortality. Additionally, these factors vary between patients receiving invasive mechanical ventilation and those in the non-invasive ventilation group. This underscores the necessity of tailoring therapeutic objectives and preventive strategies with a personalized approach.

5 May 2024 in Heliyon
Verified
Journal Article
Open access
LGLuis Fernando Giraldo-Cadavid
Luis Fernando Giraldo-Cadavid
JEJulian Echeverry
Julian Echeverry
FVFabio Varón-Vega
Fabio Varón-Vega
AGAlirio Rodrigo Bastidas Goyes
Alirio Rodrigo Bastidas Goyes
ARAndrés Ramírez-Jaime
Andrés Ramírez-Jaime
LRLuis F Reyes
Luis F Reyes
The COVID-19 pandemic in Latin America generated the need to develop low-cost, fast-manufacturing mechanical ventilators. The Universidad de La Sabana and the Fundacion Neumologica Colombiana designed and manufactured the Unisabana-HERONS (USH) ventilator. Here, we present the preclinical and clinical study results to evaluate its effectiveness and safety characteristics in an animal model (Yorkshire Sow) and five patients with acute respiratory failure receiving mechanical ventilatory support for 24 h. The effectiveness and safety outcomes included maintaining arterial blood gases and pulse oximetry saturation (SpO2), respiratory pressures and volumes (during continuous monitoring) in the range of ARDS and lung-protective strategy goals, and the occurrence of barotrauma. A significance level of 0.05 was used for statistical tests. This clinical trial was registered on Clinicaltrials.gov (NCT04497623) and approved by the ethics committee. Among patients treated with the Unisabana-HERONS, the most frequent causes of acute respiratory failure were pneumonia in 3/5 (60 %) and ARDS in 2/5 (40 %). During the treatment, the ventilatory parameters related to lung protection protocols were kept within the safety range, and vital signs and blood gas were stable. The percentage of time that the respiratory pressures or volumes were out of safety range were plateau pressure >30 cm H2O: 0.00 %; driving pressure >15 cm H2O: 0.06 %; mechanical power >15 J/min: 0.00 %; and Tidal volume >8 mL/kg: 0.00 %. There were no adverse events related to the ventilator. The usability questionnaire retrieved a median score for all items between 9 and 10 (best score: 10), indicating great ease of use. The Unisabana-HERONS ventilator effectively provided adequate gas exchange and maintained the ventilatory parameters in the range of lung protection strategies in humans and an animal model. Furthermore, it is straightforward to use and is a low-cost medical device.

12 February 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JOJuan Olivella-Gomez
Juan Olivella-Gomez
JLJulián Lozada
Julián Lozada
CSCristian C. Serrano-Mayorga
Cristian C. Serrano-Mayorga
LMLina Méndez-Castillo
Lina Méndez-Castillo
AAAlejandro Acosta-González
Alejandro Acosta-González
LRLuis F Reyes
Luis F Reyes
Purpose: Streptococcus pneumoniae (Spn) is the primary bacterial cause of lower respiratory tract infections (LRTI) globally, particularly impacting older adults and children. While Spn colonization in children is linked to LRTI, its prevalence, and consequences in adults with comorbidities remain uncertain. This study aims to provide novel data in that regard. Methods: This prospective study of outpatient adults with chronic diseases was conducted in Colombia. Data on demographics, vaccination, and clinical history was collected in a RedCap database. Nasopharyngeal aspirate samples were examined for Spn colonization using traditional cultures and quantitative—real time polymerase chain reaction (q-rtPCR). Patients were followed for 18 months, with colonization prevalence calculated and factors influencing colonization and its impact on clinical outcomes analyzed through logistic regressions. Results: 810 patients were enrolled, with 10.1% (82/810) identified as colonized. The mean (SD) age was 62 years (±15), and 48.6% (394/810) were female. Major comorbidities included hypertension (52.2% [423/810]), cardiac conditions (31.1% [252/810]), and chronic kidney disease (17.4% [141/810]). Among all, 31.6% (256/810) received the influenza vaccine in the previous year, and 10.7% (87/810) received anti-Spn vaccines. Chronic kidney disease (OR 95% CI; 2.48 [1.01–6.15], p = 0.04) and chronic cardiac diseases (OR 95% CI; 1.62 [0.99–2.66], p = 0.05) were independently associated with Spn colonization. However, colonization was not associated with the development of LRTI (OR 95%CI; 0.64 [0.14–2.79], p = 0.55) or unfavorable outcomes (OR 95% CI;1.17 [0.14–2.79], p = 0.54) during follow-up. Conclusions: Chronic kidney and cardiac diseases are independently associated with Spn colonization. However, Spn colonization was not associated with LRTI/unfavorable outcomes in adult patients with chronic comorbidities in our cohort.

4 December 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
LRLuis F Reyes
Luis F Reyes
IBIngrid G Bustos-Moya
Ingrid G Bustos-Moya
DJDiego Josa
Diego Josa
EGEnrique Gamboa-Silva
Enrique Gamboa-Silva
EIElsa Daniela Ibañez-Prada
Elsa Daniela Ibañez-Prada
ASAndrew Stewardson
Andrew Stewardson
Antimicrobial resistance (AMR) in low-income and middle-income countries (LMICs) is a public health problem. AMR is a concerning problem in Gram-negative bacteria such are Enterobacterales, which are frequently carbapenem-resistant pathogens (CRP), and few therapeutic options are available. However, scarce data is known regarding the clinical, molecular characteristics, and clinical outcomes of patients infected with carbapenem-resistant pathogens in LMICs. Thus, this study will attempt to bring novel data in these regards. This is a retrospective cohort study conducted in two reference hospitals in Colombia, South America. All consecutive patients infected with CRPs between 2017 and 2021 were included. Clinical data were gathered by retrospective chart review. Bacterial pathogens and antibiotic susceptibility were prospectively identified and stored by each hospital. Molecular characterization was performed by PCR in isolated bacteria. A total of 220 patients were included. The mean (SD) age was 60.6 (18.4) years, and 32% (71/220) were female. The most frequently identified CRPs were Pseudomonas aeruginosa (85/220, 39%) and Klebsiella pneumoniae (81/220, 37%). CRPs were most frequently identified in urine, blood, and respiratory samples (Figure 1). Community-acquired infections were frequently diagnosed in patients infected with CRPs in our study (73% [161/220]), and most of the patients were admitted to the ICU (163/220, 74%). The in-hospital mortality rate was 28% (62/220) and 38% (62/163) in ICU admitted patients. PCR was carried out in 105 CRP; KPC (69%, 73/105) and VIM (37%, 39/105) were the most frequently identified mechanisms. Of the K. pneumoniae isolates with PCR assessment, 94% (33/35) had KPC and 3% (1/35) had VIM. In contrast, in P. aeruginosa isolates with PCR assessment, 53% (29/54) had KPC and 59% (32/54) had VIM. Seven (13%) patients infected with P. aeruginosa had both KPC and VIM genes identified. The most frequently identified carbapenem-resistant pathogens in these two Colombian reference hospitals were P. aeruginosa and K. pneumoniae, with high mortality rates. KPC was the most commonly identified mechanism of carbapenem resistance in our cohort. All Authors: No reported disclosures